Drug Profile
Hib CRM197 vaccine conjugate - Nuron
Alternative Names: HibTITER; MT-2301; NU300Latest Information Update: 09 Feb 2017
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Mitsubishi Tanabe Pharma Corporation; Nuron Biotech; Wyeth
- Class Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilus infections
Most Recent Events
- 09 Feb 2017 No development reported - Phase-II for Haemophilus infections (In infants, Prevention) in USA (IM)
- 06 Feb 2017 Discontinued - Phase-II for Haemophilus infections (In infants, Prevention) in Japan (IM) (Mitsubishi Tanabe Pharma pipeline, February 2017)
- 02 Aug 2016 Phase-II development in Haemophilus infections (In infants, Prevention) is ongoing in Japan (Mitsubishi Tanabe Pharma Pipeline, August 2016)